During Thursday’s Morning trade, Shares of Xilinx, Inc. (NASDAQ:XLNX), lost -0.13% to $48.94.
Xilinx, declared the Vivado® Design Suite HLx Editions, enabling a new ultra high productivity approach for designing All Programmable SoCs, FPGAs, and the creation of reusable platforms. These new HLx Editions comprise HL System Edition, HL Design Edition and HL WebPACK™ Edition. All HLx Editions comprise Vivado High-Level Synthesis (HLS) counting C/C++ libraries, Vivado IP Integrator (IPI), LogicCORE™ IP subsystems, and the full Vivado implementation tool suite to enable mainstream users to readily adopt the most productive and advanced C and IP-based design flows. When coupled with the new UltraFast™ High-Level Productivity Design Methodology Guide, users can realize a 10-15X productivity gain over traditional approaches. The HLx Edition is available as a no-cost upgrade to the Vivado Design Suite.
Ultra High Productivity for Creating and Programming Reusable Platforms
Over the last 3 years, leading edge Xilinx customers have pioneered and matured the enabling C and IP-based design technologies and methodologies now comprised in the HLx Editions, and proven the 10-15X productivity potential. To realize this productivity, these customers adopted all or a subset of the following; 1) C-based design and optimized reuse, 2) reuse of IP subsystems, 3) integration automation, and 4) accelerated design closure.
Unlike tradition RTL-based design where the majority of the design effort is spent in the backend of the design process, C and IP-based design enables vastly superior design reuse to speed creation, rapid design exploration for better micro-architectures, replaces error prone manual C to RTL conversion, eliminates time and errors while integrating C and RTL-based IP, and dramatically shortens verification time. Using high levels of abstraction, customers have found that they can quickly get overall better or equal Quality of Results (performance, power, utilization).
Xilinx, Inc. designs and develops programmable devices and associated technologies worldwide. Its programmable devices comprise integrated circuits (ICs) in the form of programmable logic devices (PLDs), such as programmable system on chips, and three dimensional ICs; software design tools to program the PLDs; targeted reference designs; printed circuit boards; and intellectual property (IP), which comprises of Xilinx and various third-party verification and IP cores.
Shares of Tidewater Inc. (NYSE:TDW), inclined 2.63% to $8.97, during its current trading session.
Tidewater, declared that Joseph M. Bennett, Executive Vice President and Chief Investor Relations Officer, will present at the Capital One Securities, Inc. 10th Annual Energy Conference in New Orleans, Louisiana on Thursday, December 10, 2015, at about 9:40 a.m. Central time.
Tidewater Inc. provides offshore service vessels and marine support services through the operation of a fleet of marine service vessels to the offshore energy industry worldwide. The company operates in Americas, Asia/Pacific, Middle East/North Africa, and Sub-Saharan Africa/Europe segments.
Finally, Shares of bluebird bio Inc (NASDAQ:BLUE), gained 0.77%, and is now trading at $81.63.
bluebird bio, and ViroMed Co., declared that they have reached an exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies using ViroMed’s proprietary humanized antibody to an unrevealed cancer target for solid tumors.
Under the terms of the agreement, ViroMed will provide bluebird bio exclusive rights to its novel humanized antibody to the target, and bluebird bio will leverage its proprietary lentiviral gene therapy platform and CAR T capabilities to develop CAR T therapies against the target. Financial terms of the agreement comprise a $1 million upfront payment and subsequent milestone payments to ViroMed, which together could total over $48 million per licensed product if certain development and regulatory milestones are achieved. ViroMed is also eligible to receive tiered royalties on product sales. bluebird bio will conduct and fund clinical development in addition to regulatory and commercial activities.
“Over the course of 2015, bluebird has continued to expand its immuno-oncology research and preclinical programs, building a broad pipeline of multiple targets in solid and hematologic malignancies. We are happy to enter this agreement with ViroMed and add their novel target to our growing pipeline,” said Rob Ross. M.D., head of oncology, bluebird bio. “We believe that this target, combined with our lentiviral vector and manufacturing expertise, position us as a leader in delivering potentially transformative T cell-based immunotherapies to patients.”
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic and rare diseases. Its advanced product candidate is Lenti-D, which is in phase II/III clinical studies for the treatment of childhood cerebral adrenoleukodystrophy, a rare, hereditary neurological disorder affecting young boys; and LentiGlobin that is in phase I/II clinical studies for the treatment of beta-thalassemia major and severe sickle cell disease (SCD) in France, in addition to a phase I study in the United States for the treatment of severe SCD.